Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi / Rigolin, G. M.; Soddu, S.; Dondolin, R.; Frustaci, A. M.; Scortechini, I.; Mauro, F. R.; Angotzi, F.; Motta, M.; Scarfo, L.; Mengarelli, A.; Giordano, A.; Martinelli, S.; Patti, C.; Sportoletti, P.; Sanna, A.; Maschio, N.; Riccioni, R.; Vigano, C. V.; Tafuri, A.; Piciocchi, A.; Fazi, P.; Luminari, S.; Ferreri, A. J. M.; Gini, G.; Ghia, P.; Cuneo, A.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - (2026). [10.1111/bjh.70401]
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi
Scarfo L.;Maschio N.;Ferreri A. J. M.;Ghia P.
;
2026-01-01
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
